Defence Therapeutics Enhances In-House ADC Development Platform with Expanded Analytical and Cellular Testing Capabilities

Montreal, Quebec--(Newsfile Corp. - May 19, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the expansion of internal capabilities to execute critical stages of its ACCUM®-enabled Antibody Drug Conjugates ("ADC") development pipeline. The Company has strengthened its purification, analytical characterization, conjugation development, and quality control ("QC") capabilities, while enhancing cellular testing and potency evaluation workflows within a more structured stage-gated framework to better support the advancement of its ADC partnership programs.